Vtesse, which has spun-off from accelerator Cydan Development, secured the funding from backers including Pfizer and Lundbeck.
US-based rare disease drug developer Vtesse raised $25m yesterday in a series A round featuring pharmaceutical corporate venturing units Pfizer Venture Investments and Lundbeckfond Ventures.
Pfizer Venture Investments, the corporate venturing arm of Pfizer, and Lundbeckfond Ventures, which fulfils the same function for Lundbeck, were joined by New Enterprise Associates, which led the round, Bay City Capital and Alexandria Venture Investments.
Vtesse, a spin-off of orphan-drug accelerator Cydan Development, will use the funding to support work on a treatment it…
